Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 6 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Overview | 8 | 1 |
| Therapeutics Development | 9 | 4 |
| CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Products under Development by Stage of Development | 9 | 1 |
| CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Products under Development by Therapy Area | 10 | 1 |
| CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Products under Development by Indication | 11 | 2 |
| CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Pipeline Products Glance | 13 | 2 |
| Late Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Products under Development by Companies | 15 | 3 |
| CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Products under Development by Universities/Institutes | 18 | 2 |
| CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Therapeutics Assessment | 20 | 7 |
| Assessment by Monotherapy/Combination Products | 20 | 1 |
| Assessment by Mechanism of Action | 21 | 2 |
| Assessment by Route of Administration | 23 | 2 |
| Assessment by Molecule Type | 25 | 2 |
| CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Companies Involved in Therapeutics Development | 27 | 8 |
| Biogen, Inc. | 27 | 1 |
| Bristol-Myers Squibb Company | 28 | 1 |
| eTheRNA Immunotherapies NV | 29 | 1 |
| ImmuNext, Inc. | 30 | 1 |
| Juno Therapeutics Inc. | 31 | 1 |
| MedImmune, LLC | 32 | 1 |
| Targovax AS | 33 | 1 |
| XL-protein GmbH | 34 | 1 |
| CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Drug Profiles | 35 | 21 |
| Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD Drug Profile | 35 | 1 |
| Antibody to Target CD40 Ligand for Immunology Drug Profile | 36 | 1 |
| BIIB-063 Drug Profile | 37 | 1 |
| BMS-986004 Drug Profile | 38 | 1 |
| Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies Drug Profile | 39 | 2 |
| FFP-102 Drug Profile | 41 | 1 |
| hepatitis B vaccine Drug Profile | 42 | 1 |
| ISF-35 Drug Profile | 43 | 2 |
| LOAd-700 Drug Profile | 45 | 1 |
| MEDI-4920 Drug Profile | 46 | 1 |
| MegaCD40L Drug Profile | 47 | 1 |
| Oligonucleotide to Activate CD40L, CD70 and TLR-4 for Oncology and Infectious Diseases Drug Profile | 48 | 1 |
| ONCOS-402 Drug Profile | 49 | 1 |
| TDI-28 Drug Profile | 50 | 1 |
| TDI-846 Drug Profile | 51 | 1 |
| UltraCD40L Drug Profile | 52 | 1 |
| Vaccine to Target CD40L and GM-CSF for Oncology Drug Profile | 53 | 2 |
| XL-050 Drug Profile | 55 | 1 |
| CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Dormant Projects | 56 | 2 |
| CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Featured News &Press Releases | 58 | 6 |
| Nov 17, 2015: Memgen Announces Preclinical Results for ISF35 in Combination with Checkpoint Inhibitors in a Model of Metastatic Melanoma | 58 | 1 |
| Dec 07, 2011: Memgen Announces Upcoming Presentation For ISF35 In Chronic Lymphocytic Leukemia At 2011 ASH Annual Meeting | 58 | 1 |
| Jun 21, 2011: Memgen Presents Clinical Results For ISF35 In Chronic Lymphocytic Leukemia At ASCO 2011 | 59 | 1 |
| Dec 09, 2010: Memgen Announces Clinical And Preclinical Results For ISF35 In Chronic Lymphocytic Leukemia And Non-Hodgkin's Lymphoma | 59 | 1 |
| Dec 08, 2009: Memgen Announces Positive Data Results Of ISF35 For Chronic Lymphocytic Leukemia | 60 | 1 |
| Dec 08, 2009: Memgen's ISF35 Sensitizes Cancer Cells To Chemotherapy | 61 | 1 |
| Dec 02, 2009: Memgen Selects Clinical Trial Results Of ISF35 For An Oral Presentation At ASH 2009 Annual Meeting | 61 | 1 |
| Dec 01, 2009: Memgen's Clinical Trial Results Of ISF35 For Chronic Lymphocytic Leukemia Selected For Presentation At ASH 2009 Annual Meeting | 62 | 1 |
| Jun 08, 2009: Memgen Reports Positive Results For ISF35 In High-Risk Chronic Lymphocytic Leukemia | 62 | 1 |
| Jun 04, 2009: Memgen Reports Positive Results For ISF35 In High-Risk Chronic Lymphocytic Leukemia | 62 | 2 |
| Appendix | 64 | 2 |
| Methodology | 64 | 1 |
| Coverage | 64 | 1 |
| Secondary Research | 64 | 1 |
| Primary Research | 64 | 1 |
| Expert Panel Validation | 64 | 1 |
| Contact Us | 64 | 1 |
| Disclaimer | 65 | 1 |